University of Illinois at Chicago
Announcement of an Exempt Purchase
Vendor: Cardinal Health, Dublin, OH
Amount: An estimated $975,000
An estimated start date of 7/1/2018 through 6/30/2020
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Tuesday, June 12, 2018
The University awarded a contract for Ra 223 (Xofigo) drug.
This drug is for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastases. Algeta is the sole manufacturer of Ra 223 (Xofigo) and Cardinal Health is the sole distributor in the United States.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) Currently Ra 223 is the only isotope available for treatment of patients with castration-resistant prostate cancer. Ra 223 is required for patient care.
For additional information, contact:
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.